Media

Nexstim Plc receives R&D loan from Business Finland

Emil Billbäck appointed CEO of BONESUPPORT

Strongbridge Biopharma plc Announces Proposed Public Offering of 5 Million Ordinary Shares

PUBLICATION HIGHLIGHTS A NOVEL CERAMENT® CARRIER WITH BONE ACTIVE AGENTS ENHANCING BONE FORMATION

Strongbridge Biopharma Receives Notice of Allowance from U.S. Patent and Trademark Office for New Patent Covering RECORLEV™ (levoketoconazole) for the Treatment of Cushing’s Syndrome

Strongbridge Biopharma Receives Notice of Allowance from U.S. Patent and Trademark Office for New Patent Covering RECORLEV™ (levoketoconazole) for the Treatment of Cushing’s Syndrome

Strongbridge Biopharma plc Announces Acquisition of the U.S. and Canadian Rights to MACRILEN™ (macimorelin) from Aeterna Zentaris

GenSight Biologics receives MHRA approval to initiate Phase I/II PIONEER clinical trial of GS030 gene therapy in Retinitis Pigmentosa

Pulmonx Submits Premarket Approval (PMA) Application to U.S. FDA for Zephyr Endobronchial Valve as Treatment for Emphysema

BioClin Therapeutics Appoints Graeme Currie, Ph.D., as Chief Operating Officer and Esteban (Steve) Abella, M.D., as Chief Medical Officer